Search

Series:

Dose and Delivery

With Inder Paul Singh, MD

Targeting the Conventional Outflow System

Inder Paul Singh, MD, Mark J. Gallardo, MD

Show Description +

Mark Gallardo, MD, sits down with Inder Paul Singh, MD, to talk about latanoprostene bunod ophthalmic solution 0.024% (Vyzulta, Bausch + Lomb). Learn more about this molecule and how it differs from other commercially available agents.

Posted: 4/23/2020

Up Next

The Diagnostic Value of Corneal Hysteresis

The Diagnostic Value of Corneal Hysteresis

Davinder Grover, MD, Inder Paul Singh, MD

The Importance of Understanding Mechanism of Action

The Importance of Understanding Mechanism of Action

I. Paul Singh, MD, Jacob W. Brubaker, MD, Jason Bacharach, MD

Addressing Ocular Surface Disease

Addressing Ocular Surface Disease

Christopher Starr, MD, Inder Paul Singh, MD, Sumitra S. Khandelwal, MD

The Evolution of Target IOP

The Evolution of Target IOP

Carlos Buznego MD, Inder Paul Singh, MD, Jason Bacharach MD

Defining Success in Glaucoma Management

Defining Success in Glaucoma Management

Ehsan Sadri, MD, Inder Paul Singh, MD, Manjool Shah, MD

More Choices in Prostaglandin Analogues

More Choices in Prostaglandin Analogues

Gregory Katz, MD, Inder Paul Singh, MD

New Horizons in Drug Delivery

New Horizons in Drug Delivery

Arsham Sheybani, MD, Inder Paul Singh, MD, Jacob W. Brubaker, MD

Back to All Videos

Targeting the Conventional Outflow System

Inder Paul Singh, MD, Mark J. Gallardo, MD

Mark Gallardo, MD, sits down with Inder Paul Singh, MD, to talk about latanoprostene bunod ophthalmic solution 0.024% (Vyzulta, Bausch + Lomb). Learn more about this molecule and how it differs from other commercially available agents.

Posted: 4/23/2020

Please log in to leave a comment.

Comments

Saeed Shalaby

5 years ago

This discussion is a nice one,but can be supported by papers,videos or any illustrations.